The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Holler Frank A since 2015.
This trader's CIK number is 938801.
At the time of last reporting, Holler Frank A was the Director of Xenon Pharmaceuticals Inc.. (stock ticker symbol XENE).
Also see all insider trading activities at Xenon Pharmaceuticals Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | XENE | 0 | $0 | 11,064 | $206,730 | 39,094 | $146,993 |
| 2020 | XENE | 0 | $0 | 0 | $0 | 3,086 | $10,986 |
| 2019 | XENE | 0 | $0 | 22,243 | $207,114 | 31,892 | $103,872 |
| 2018 | XENE | 0 | $0 | 0 | $0 | 3,086 | $11,634 |
| 2016 | XENE | 0 | $0 | 60,000 | $469,992 | 0 | $0 |
| 2015 | XENE | 0 | $0 | 0 | $0 | 4,114 | $20,980 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-05-27 | XENE | Option Ex | 39,094 | 3.76 | 146,993 |
| 2021-05-27 | XENE | Sale | 11,064 | 18.68 | 206,730 |
| 2020-05-29 | XENE | Option Ex | 3,086 | 3.56 | 10,986 |
| 2019-09-19 | XENE | Sale | 7,600 | 9.27 | 70,452 |
| 2019-09-20 | XENE | Sale | 5,206 | 9.39 | 48,884 |
| 2019-09-17 | XENE | Sale | 5,069 | 9.32 | 47,243 |
| 2019-09-18 | XENE | Sale | 4,368 | 9.28 | 40,535 |
| 2019-09-12 | XENE | Option Ex | 31,892 | 3.26 | 103,872 |
| 2018-03-14 | XENE | Option Ex | 3,086 | 3.77 | 11,634 |
| 2016-12-15 | XENE | Sale | 30,000 | 7.85 | 235,500 |
| 2016-08-19 | XENE | Sale | 11,938 | 7.65 | 91,337 |
| 2016-08-16 | XENE | Sale | 6,863 | 8.25 | 56,619 |
| 2016-08-17 | XENE | Sale | 1,600 | 7.89 | 12,624 |
| 2016-08-18 | XENE | Sale | 9,599 | 7.70 | 73,912 |
| 2015-11-24 | XENE | Option Ex | 2,057 | 5.22 | 10,737 |
| 2015-08-18 | XENE | Option Ex | 2,057 | 4.98 | 10,243 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Holler Frank A (Director of Xenon Pharmaceuticals Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.